Phase 3 results presented in Munich and Barcelona show gains for two life-threatening conditions that quietly steal years from older adults.
Four late-breaking trials. Two European conferences, back to back. And a set of drug names – ralinepag, treprostinil – that don’t mean much to anyone outside a cardiology ward. That’s the unglamorous surface of what United Therapeutics just put in front of doctors at the European Society of Cardiology Congress in Munich and the European Respiratory Society Congress in Barcelona. Underneath it, though, is a genuinely useful update on two diseases that tend to get diagnosed too late and treated too cautiously: pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF).
United Therapeutics is the company Martine Rothblatt built after her daughter was diagnosed with PAH decades ago, and it’s still, at its core, chasing better outcomes for that same disease and its close relatives. This week’s data dump, four oral presentations and four posters, covers ground from a large phase 3 trial down to a screening study still in its early days [1].
The subgroup that usually gets left behind
Start with ADVANCE OUTCOMES, the biggest of the four. It tested an investigational drug called ralinepag in PAH patients, and the topline result was solid: meaningful clinical improvement in a lower-risk patient population. What stood out more, honestly, was the secondary finding, a benefit in patients whose PAH is complicated by connective tissue disease. That’s a subgroup where blood vessel damage tends to move faster and where drugs that work in “typical” PAH often underperform. Getting a signal there is the harder win.
Most people don’t catch PAH early. Breathlessness on the stairs, a bit more tired than usual. It reads as aging, not disease, until the right side of the heart is already working overtime against arteries that have stiffened and narrowed. A therapy that moves the needle in the toughest subgroup is a therapy that’s actually being tested where it counts.
Dosing that scales with benefit
The second dataset, from the TETON program, looked at nebulized treprostinil in IPF, a disease where lung tissue slowly scars until each breath takes more effort than the last. Patients on the inhaled therapy showed improved lung function and fewer serious flare-ups. The detail that mattered most to the trial statisticians: the benefit increased with dose. That kind of dose-response pattern is one of the more convincing signs, in drug development, that an effect is genuine and not statistical noise.
A related interim readout, from the ARTISAN study, tested treprostinil delivered straight into the bloodstream in PAH patients. Starting high and titrating fast improved right ventricular ejection fraction, a measure of how well the heart’s overworked chamber is pumping, over 12 months.
A screening tool that may be missing people
Then there’s PHINDER, still preliminary, but arguably the most quietly important of the four. It’s built to answer a narrower question: how well does standard echocardiography actually catch pulmonary hypertension in patients who already have interstitial lung disease, a population where the two conditions overlap and compound each other constantly? Early results suggest the standard screening tool has real limitations, meaning some patients who’d benefit from earlier treatment may currently be slipping through.
Dr Franck Rahaghi, United Therapeutics’ chief medical officer, put the whole push in context: “This year at ERS and ESC, we are presenting data that reflect the breadth of our work to deepen our understanding of how appropriate treatment may improve outcomes for people living with life-threatening diseases like PAH, PH-ILD, and IPF.”
“We remain committed to generating meaningful evidence across both established and investigational therapies to help advance the standard of care for these patient populations,” he added.
Worth flagging: none of this is FDA-approved. Applications for ralinepag and nebulized treprostinil went in this past June, and both drugs remain investigational until regulators weigh in.
PAH and IPF rarely show up in longevity headlines the way epigenetic clocks or supplements do, but they belong in the conversation. Both are diseases that quietly compress how many good years a person gets, and both get diagnosed later than they should. Better screening tools and drugs that work in the sickest subgroups don’t extend life through some flashy mechanism; they just keep hearts and lungs functional long enough for everything else to hold up.
